ViiV Healthcare looks to make long-acting HIV prevention shot accessible in low- and middle-income countries

The Joint United Nations Programme on HIV and AIDS set a lofty goal back in 2019 to end the HIV epidemic by 2030. But according to the World Health Organization, infection rates are not falling rapidly enough to meet that target.

GSK’s ViiV Healthcare thinks it can help change that.


Click to view original post